Clinical Trails

Clinical Vaccine Trials

Clinical vaccine trials are being conducted in a variety of departments throughout Jefferson.

Primary Care Clinical Trials

Christopher V. Chambers, MD, Director
Lori Conley, RN, Coordinator
Phone: 215-955-4720
Fax: 215-973-2363

Primary Care Clinical Trials (PCCT) performs a wide variety of clinical research studies under the auspices of the Department of Family and Community Medicine at Thomas Jefferson University. The department’s clinical practice provides care to more than 40,000 patients, a diverse population which is representative of the greater Philadelphia metropolitan area, who make approximately 80,000 outpatient visits per year. Our experienced research staff includes full-time Faculty, Clinical Fellows, a Clinical Research Nurse, research assistants and other administrative professionals. The PCCT’s clinical trials focus on the prevention and management of chronic diseases.

Vaccine studies recently completed or currently in progress.

HIV Clinical Trials

Department of Medicine
Division of Infectious Diseases
HIV Clinical Trials Unit
Kathleen E. Squires, MD, Director
Gwen Verlinghieri, RN, Coordinator
Phone: 215-503-9060
Fax: 215-503-2624

The HIV Clinical Trials Unit (CTU) conducts clinical research studies to define optimal management strategies for the treatment of HIV infection and related opportunistic infections and/or complications through an NIH-funded network, the AIDS Clinical Trials Group, and collaborations with the pharmaceutical industry. The Jefferson University Physicians HIV clinic care to more than 600 patients.

In the News

New Funding for JVC Members

Dr. McGettigan, was awarded a four-year $1.5 million R01 grant from the NIH to extend his exciting work on the development of a novel, safe, and effective rabies virus vaccine.

A Team of Researchers from Fox Chase, Jefferson and Penn State Receive NIAID Grant for Viral Control. Both Dr. Luis Sigal and Dr. Eisenlohr are members of the JVC. The team to receive a total of approximately $2 million each year for the next five years. For more information ...

Dr. David Abraham received a five year R01 grant to study the development of a recombinant vaccine against human onchocerciasis.

The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement